Key Takeaways
- Kyverna’s CAR-T therapy miv-cel (KYV-101) met its goals in the phase 2 KYSA-8 trial for stiff-person syndrome, with a median 46% improvement in walking speed at week 16.
- The company has begun a rolling BLA with the FDA, chasing the milestone of the first CAR-T cell therapy approved for an autoimmune disease rather than cancer.
- Safety looked clean for CAR-T: no high-grade CRS or ICANS, the two dangerous immune reactions that usually shadow this technology.
CAR-T leaves the cancer ward
CAR-T therapy was built to fight blood cancers. You pull a patient’s T cells, re-engineer them to hunt a target, and put them back to wipe out the malignant cells. What Kyverna is betting on is that the same weapon works on autoimmune disease, where the problem is not cancer but rogue B cells attacking the body’s own tissue. Clear out those B cells and the autoimmune attack can reset.
Miv-cel, also called KYV-101, is a CD19-targeted CAR-T that Kyverna licensed from the NIH. The disease it is aimed at first is stiff-person syndrome (SPS), a rare neuro-immune disorder that causes disabling muscle rigidity and spasms and can gradually rob people of the ability to walk. There is no FDA-approved therapy specifically for it, so the bar to clear is a real unmet need.
What KYSA-8 delivered
The registrational phase 2 KYSA-8 trial dosed 26 patients. At the week 16 primary analysis, the results were strong.
| Measure | Result |
|---|---|
| Median improvement, timed 25-foot walk | 46% vs baseline (p=0.0002) |
| Patients beating 20% walk improvement | 81% |
| Secondary endpoints | All highly significant (p<0.0001) |
| Serious CAR-T toxicity (CRS/ICANS) | None high-grade |
| Notable adverse event | Grade 3/4 neutropenia |
The headline is the walking. A median 46% faster timed walk is a large functional gain for a disease that steadily takes mobility away, and more than four in five patients cleared the threshold doctors consider clinically meaningful. Every secondary measure moved the same direction.
The safety read matters just as much. CAR-T’s reputation is built partly on two feared reactions, cytokine release syndrome and neurotoxicity. Neither showed up at high grade here. The low white-cell counts (neutropenia) are the expected cost of the conditioning that comes with cell therapy.
The regulatory play
Kyverna has already started a rolling BLA submission, filing pieces as they are ready rather than waiting to hand in everything at once. That followed a positive pre-BLA meeting where the FDA agreed the single-arm KYSA-8 trial could support the application. Miv-cel carries RMAT (regenerative medicine advanced therapy) designation, which can unlock priority review and faster feedback.
If it lands, the significance runs past one rare disease. It would be the first CAR-T cleared for autoimmunity, and that opens a much larger door. Kyverna and others are already eyeing conditions like myasthenia gravis and progressive multiple sclerosis with the same logic: wipe the pathogenic B cells, reset the immune attack, ideally with a single infusion instead of lifelong immunosuppression. SPS is the proof-of-concept the whole approach is riding on.
Sources:
- Kyverna Therapeutics, “Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101)”
- BioSpace, “How Kyverna Rode CAR-T’s Autoimmune Wave to the FDA’s Door”
- Managed Healthcare Executive, “Kyverna to submit BLA for investigational CAR-T therapy for stiff-person syndrome”
Disclaimer: This article is for general information only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider about any medical condition or before making health decisions.